Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nowadays, there have been increasing studies comparing metformin with insulin. But the use of metformin in pregnant women is still controversial, therefore, we aim to examine the efficiency and safety of metformin by conducting a meta-analysis of randomized controlled trials (RCTs) comparing the effects of metformin with insulin on glycemic control, maternal and neonatal outcomes in gestational diabetes mellitus (GDM). METHODS: We used the key words "gestational diabetes" in combination with "metformin" and searched the databases including Pubmed, the Cochrane Library, Web of knowledge, and Clinical Trial Registries. A random-effects model was used to compute the summary risk estimates. RESULTS: Meta-analysis of 5 RCTs involving 1270 participants detected that average weight gains after enrollment were much lower in the metformin group (n = 1006, P = 0.003, SMD = -0.47, 95%CI [-0.77 to -0.16]); average gestational ages at delivery were significantly lower in the metformin group (n = 1270, P = 0.02, SMD = -0.14, 95%CI [-0.25 to -0.03]); incidence of preterm birth was significantly more in metformin group (n = 1110, P = 0.01, OR = 1.74, 95%CI [1.13 to 2.68]); the incidence of pregnancy induced hypertension was significantly less in the metformin group (n = 1110, P = 0.02, OR = 0.52, 95%CI [0.30 to 0.90]). The fasting blood sugar levels of OGTT were significantly lower in the metformin only group than in the supplemental insulin group (n = 478, P = 0.0006, SMD = -0.83, 95%CI [-1.31 to -0.36]). CONCLUSIONS: Metformin is comparable with insulin in glycemic control and neonatal outcomes. It might be more suitable for women with mild GDM. This meta-analysis also provides some significant benefits and risks of the use of metformin in GDM and help to inform further development of management guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The finding that metformin decreased the frequency of preeclampsia was consistent with the findings reported in a meta-analysis by Gui et al.(75) and Feng and Yang(76).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gui et al.(75) published a systematic review and meta-analysis in which metformin was shown to be superior to insulin in reducing maternal weight gain during pregnancy as well as in the frequency of gestational hypertension (Figure 5a,); however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
In the citing paper
“Gui et al.(75) published a systematic review and meta-analysis in which metformin was shown to be superior to insulin in reducing maternal weight gain during pregnancy as well as in the frequency of gestational hypertension (Figure 5a,); however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
In the citing paper
“however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(75).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390 · cited 1×
“Furthermore, the influence of the intrauterine hyperglycemia environment might go with the children in later life [3], [9].”
BackgroundEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Metzger, B. E., Gabbe, S. G., Persson, B., Lowe, L. P., Dyer, A. R., Oats, J. J. N., & Buchanan, T. A. (2010) · Diabetes Care · doi:10.2337/dc10-0719 · Cited by 1,888
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720 · cited 1×
“The possible explanation might be that metformin has complex properties on endothelial functions and reactive oxygen species production [34], so as to reduce the endothelial activation and maternal inflammatory response of insulin resistance.”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 5×
“In this meta-analysis, the incidence of requiring additional insulin to achieve euglycemia was especially high in the study of Rowan [27] (46.”
BackgroundMethodResultInfluentialKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“Metformin reduces hyperglycemia by suppressing hepatic glucose output (hepatic gluconeogenesis), increasing insulin sensitivity and enhancing peripheral glucose uptake [30].”
BackgroundEpidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856 · cited 1×
“First, the presence of GDM always accompanies an increased maternal risk for preeclampsia, cesarean section, and with an increased risk for developing type 2 diabetes (T2D) after pregnancy [3], [4].”
Backgroundde Veciana, M., Major, C. A., Morgan, M. A., Asrat, T., Toohey, J. S., Lien, J. M., & Evans, A. T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331901 · Cited by 666 · cited 1×
“In addition, there is an increased risk for neonatal death, still birth and congenital defects [5] resulting from excessive mother-to-fetus glucose transfer [6], [7].”
BackgroundMetformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379 · cited 1×
“[32] on this issue are both encouraging and reassuring which intrigue the possibility of Figure 3.”
BackgroundEsakoff, T. F., Cheng, Y. W., Sparks, T. N., & Caughey, A. B. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.02.035 · Cited by 264 · cited 1×
“Another major complication is macrosomia, which is a risk factor for instrumental delivery, cesarean section and shoulder dystocia during delivery and neonatal hypoglycemia directly after birth [8].”
BackgroundFrench Multicentric Survey of Outcome of Pregnancy in Women With Pregestational Diabetes
Diabetes and Pregnancy Group, F. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2990 · Cited by 257 · cited 1×
“In addition, there is an increased risk for neonatal death, still birth and congenital defects [5] resulting from excessive mother-to-fetus glucose transfer [6], [7].”
BackgroundGlueck, C. J. (2004) · Human Reproduction · doi:10.1093/humrep/deh263 · Cited by 250 · cited 1×
“A study followed the neonates whose mothers received metformin and found that they displayed normal weight and social and motor skills at 6 months and there were no differences in height, weight, motor, or social skills between the neonatal groups at 18 months [31].”
Dempsey, J. C., Butler, C. L., Sorensen, T. K., Lee, I.-M., Thompson, M. L., Miller, R. S., Frederick, I. O., & Williams, M. A. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.03.010 · Cited by 236 · cited 2×
“First, the presence of GDM always accompanies an increased maternal risk for preeclampsia, cesarean section, and with an increased risk for developing type 2 diabetes (T2D) after pregnancy [3], [4].”
BackgroundIjäs, H., Vääräsmäki, M., Morin-Papunen, L., Keravuo, R., Ebeling, T., Saarela, T., & Raudaskoski, T. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02763.x · Cited by 215 · cited 2×
“The quality assessments of the included studies Tertti [25], Alavi [26], Ijas [17], Rowan [27], Moore [28] are presented in Table 3.”
BackgroundNiromanesh, S., Alavi, A., Sharbaf, F. R., Amjadi, N., Moosavi, S., & Akbari, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.031 · Cited by 203 · cited 1×
“The quality assessments of the included studies Tertti [25], Alavi [26], Ijas [17], Rowan [27], Moore [28] are presented in Table 3.”
BackgroundTertti, K., Ekblad, U., Koskinen, P., Vahlberg, T., & Rönnemaa, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12017 · Cited by 174
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145 · cited 2×
“The results are the same as the previous reviews [14], [29] that metformin is comparable with insulin in glycemic control.”
ResultBalani, J., Hyer, S. L., Rodin, D. A., & Shehata, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02780.x · Cited by 145
Moore, L. E., Briery, C. M., Clokey, D., Martin, R. W., Williford, N. J., Bofill, J. A., & Morrison, J. C. (2007) · PubMed · Cited by 123
Metformin for gestational diabetes in routine clinical practice
Goh, J. E. L., Sadler, L., & Rowan, J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03361.x · Cited by 99
Transfer of metformin across the dually perfused human placental lobule
Nanovskaya, T. N., Nekhayeva, I. A., Patrikeeva, S. L., Hankins, G. D. V., & Ahmed, M. S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.047 · Cited by 98 · cited 1×
“Given that metformin has been found to have a maternal-to-fetal transfer rate of 10–16% [18], [19] which might be associated with fetal anomalies, potential adverse effects for mothers and the newborns after delivery, it has not been widely used in GDM.”
BackgroundGlycemia and Its Relationship to Outcomes in the Metformin in Gestational Diabetes Trial
Rowan, J. A., Gao, W., Hague, W. M., & McIntyre, H. D. (2010) · Diabetes Care · doi:10.2337/dc09-1407 · Cited by 96 · cited 1×
“In addition, there is an increased risk for neonatal death, still birth and congenital defects [5] resulting from excessive mother-to-fetus glucose transfer [6], [7].”
BackgroundKovo, M., Haroutounian, S., Feldman, N., Hoffman, A., & Glezerman, M. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.01.013 · Cited by 94
Tertti, K., Ekblad, U., Vahlberg, T., & Rönnemaa, T. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.95 · Cited by 91
Metformin - A convenient alternative to insulin for Indian women with diabetes in pregnancy
Rai, L., Meenakshi, D., & Kamath, A. (2009) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.58878 · Cited by 75 · cited 1×
“However, some are case-control trials [2022], some are observational studies [23], others are randomized controlled trials (RCTs) but with small samples lacking the power to draw confirmative conclusions on the relative risks and benefits of metformin for GDM.”
BackgroundOral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety
Nicholson, W., & Baptiste-Roberts, K. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.018 · Cited by 72 · cited 3×
“The results are the same as the previous reviews [14], [29] that metformin is comparable with insulin in glycemic control.”
BackgroundResultShould we continue or stop insulin sensitizing drugs during pregnancy?
Norman, R. J., Wang, J. X., & Hague, W. (2004) · Current Opinion in Obstetrics and Gynecology · doi:10.1097/00001703-200406000-00007 · Cited by 71 · cited 1×
“However, insulin has several disadvantages including multiple daily injections, the risk of hypoglycemia and maternal weight gain [15].”
BackgroundOral hypoglycemic agents for gestational diabetes mellitus?
Maymone, A. C., Baillargeon, J.-P., Ménard, J., & Ardilouze, J.-L. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.521740 · Cited by 41 · cited 2×
“GDM, the most frequent medical complication of pregnancy, is associated with several adverse outcomes over the short- and long-term for both mother and offspring [2].”
BackgroundUpdate on Gestational Diabetes Mellitus
Evensen, A. E. (2011) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2011.11.011 · Cited by 40 · cited 1×
“Therefore, active treatments - such as dietary therapy, exercise, oral hypoglycemic agents, insulin - are necessary to reduce the complications [11].”
BackgroundThe contentious nature of gestational diabetes: diet, insulin, glyburide and metformin
Glueck, C. J., Goldenberg, N., Streicher, P., & Wang, P. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.11.1557 · Cited by 38 · cited 1×
“When an appropriate diet, alone or associated with physical exercise, does not suffice to control blood glucose levels in pregnant women, subcutaneous insulin therapy has been considered the standard for management of GDM [12-14].”
BackgroundMetformin treatment for Type 2 diabetes in pregnancy?
Simmons, D. S. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.002 · Cited by 32 · cited 1×
“These effects are potentially useful during pregnancy when glucose control deteriorates with changes to insulin resistance [16].”
BackgroundA Trial in Progress: Gestational Diabetes
Rowan, J. A., & on behalf of the MiG Investigators (2007) · Diabetes Care · doi:10.2337/dc07-s219 · Cited by 32 · cited 7×
“The trial excluded was: Rowan [24]-it was a trial in process with no maternal or neonatal outcomes.”
BackgroundInfluentialSLAGLE, M. A. (2002) · Southern Medical Journal · doi:10.1097/00007611-200295010-00009 · Cited by 7
Diabetes mellitus. Medication update.
SLAGLE, M. A. (2002) · PubMed · Cited by 6
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s013 · Cited by 332
“port the efficacy and short-term safety of metformin (30,31) and glyburide (32) for the treatment of GDM, both agents”
Metadata
- Authors
- Gui, J., Liu, Q., & Feng, L.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Feng, Ling
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-27
- Volume
- 8
- Issue
- 5
- Pages
- e64585
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3664585
- OpenAlex
- W2109810300
- Cited by
- 222
- References
- 37
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 22 · 2020: 15 · 2019: 19 · 2018: 31 · 2017: 13 · 2016: 12 · 2015: 34 · 2014: 19 · 2013: 3
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, glycemic control, maternal outcomes, neonatal outcomes, preterm birth, gestational hypertension, gestational weight gain, fasting blood glucose, oral glucose tolerance test
- MeSH terms
- Birth Weight, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Metformin, Pregnancy, Pregnancy Outcome, Diabetes, Gestational, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.